Use of heme-peptides to prevent or retard disease associated wit

Details Use of heme-peptides to prevent or retard disease associated wit Use of heme-peptides to prevent or retard disease associated wit

1997-02-27

2000-01-11

Davenport, Avis M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 15, 514 16, 514 21, 530304, 530326, 530327, 530328, 530400, 530401, A61K 3800, A61K 3816, C07K 500, C07K 700

Patent

active

060136235

ABSTRACT:
This invention provides a method for treating a condition associated with oxidative stress in a subject which comprises administering to the subject an amount of a heme-peptide effective to treat the condition associated with oxidative stress in the subject. The subject may be a mammal. The mammal may be a human being. The condition associated with oxidative stress may be an inflammatory condition, an allergic condition or an auto-immune condition.

REFERENCES:
patent: 5696109 (1997-12-01), Malfroy-Camine
Abraham, Nader G. et al. (1995) Adenovirus-Mediated Heme Oxygenase-1 Gene Transfer Into Rabbit Ocular Tissues. Investigative Ophthalmology & Visual Science 36:2202-2210(Exhibit A).
Ames, Bruce N. et al. (1993) Oxidants, antioxidants, and the degenerative diseases of aging Proc. Natl. Acad. Sci. 90:7915-7922(Exhibit B).
Bodaness, Richard S. et al. (1984) An analysis of the H.sub.2 O.sub.2 -Mediated Crosslinking of Lens Crystallins Catalyzed by the Heme-Undecapeptide from Cytochrome c. Archives of Biochemistry and Biophysics 231:461-469(Exhibit C).
Bodaness, Richard S. et al. (1983) The rapid H202-mediated nonphotodynamic crosslinking of lens crystallins generated by the heme-unadecapeptide from cytochrome C: Potential implications for cataractogenesis in man. Biochemical and Biophysical Research Communications 113:592-597(Exhibit D).
Elstner, E.F. (1991) Oxygen Radicals--Biochemical Basis for their Efficacy, Klinische Wochenschrift 69:949-956(Exhibit E).
Kikugawa, Kiyomi et al. (1991) Development of fluorescence and cross-links in eye lens crystallin by interaction with lipid peroxy radicals. Biochemica et Biophysica Acta 1906; 108-114(Exhibit F).
Lysko, A.I. et al. (1990) The mechanism of the antioxidant effect of cytochrome C heme nonapeptide. Dokl Akad Nauk SSSR 315(2);500-504(Exhibit G).
Reddan, John R. et al. (1996) Regional differences in the distribution of catalase in the epithelium of the ocular lens. Cellular and Molecular Biology 42(2): 209-219(Exhibit H).
Feng Xu et al, Biochn. Biophys. Res. Comm., vol. 181, No. 1 pp. 197-203, Nov. 1991.
Spector et al., Exp. Eye. Res., vol. 65, pp. 457-470, 1997.
Lysko et al. Dokl Akad Nauk SSSR., 315 (2) (1990), 500-504.

Affiliated with

Also associated with

Rating

Use of heme-peptides to prevent or retard disease associated wit does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of heme-peptides to prevent or retard disease associated wit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of heme-peptides to prevent or retard disease associated wit will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1462392